1
|
Gagliano C, Zeppieri M, Longo A, Rubegni G, Amato R, Foti R, Cappellani F, Cocuzza M, Visalli F, Cannizzaro L, Avitabile A, Gagliano G, Lapenna L, D’Esposito F. Efficacy and Safety of Artificial Tears Containing Lipidure and Hypromellose for the Treatment of Moderate Dry Eye Disease in Contact Lens Wearers. Medicina (Kaunas) 2024; 60:287. [PMID: 38399574 PMCID: PMC10890511 DOI: 10.3390/medicina60020287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2023] [Revised: 01/30/2024] [Accepted: 02/05/2024] [Indexed: 02/25/2024]
Abstract
Background and Objectives: Dry eye disease (DED) affects 5-50% of the global population and deeply influences everyday life activities. This study compared the efficacy, tolerability, and safety of novel Respilac artificial tears containing lipidure and hypromellose (HPMC) with the widely used Nextal artificial tears, which are also HPMC-based, for the treatment of moderate DED in contact lenses (CL) wearers. Materials and Methods: In a prospective, single-center, randomized investigation, 30 patients aged ≥18 years, diagnosed with moderate DED, and wearing CL were randomly assigned to the Respilac (n = 15) or Nextal group (n = 15). Patients self-administrated one drop of Respilac or Nextal in both eyes three times daily for 21 days. Changes in the endpoint (visual analogue scale (VAS) score for ocular tolerability, symptom assessment in dry eye (SANDE) score, non-invasive first break-up time (NIF-BUT) results, tear analysis value, meibography results, and CL tolerability results were assessed, comparing treatment groups and time-point evaluations. Adverse events (AEs) were also recorded and evaluated. Results: VAS scores decreased with time (p < 0.001) in both groups, showing no statistically significant difference among them (p = 0.13). Improvements were also detected from screening to end-of-treatment, which were indicated by the SANDE scores for severity and frequency (p < 0.001) and by tear analysis results (p < 0.001) with no observed difference between the Nextal and Respilac arms. NIF-BUT, meibography, and CL tolerability values were shown to be non-significantly affected by treatment and time. There were no AEs detected in this study cohort. Conclusions: Respilac was confirmed to be effective, safe, and well-tolerated. Lipidure-based ophthalmic solution was shown not to be inferior to the currently used Nextal, however, showing improvements in DED symptoms. Within the existing literature, our study is one of the first to report that MPC plus HPMC-containing eye drops are an effective option for the treatment of moderate dry eye disease and desiccation damage prevention in contact lens wearers.
Collapse
Affiliation(s)
- Caterina Gagliano
- Faculty of Medicine and Surgery, University of Enna “Kore”, Piazza dell’Università, 94100 Enna, Italy;
- Eye Clinic, Catania University, San Marco Hospital, Viale Carlo Azeglio Ciampi, 95121 Catania, Italy
| | - Marco Zeppieri
- Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy
| | - Antonio Longo
- Faculty of Medicine, University of Catania, Piazza Università, 95123 Catania, Italy (L.C.); (A.A.)
| | - Giovanni Rubegni
- Faculty of Medicine, University of Catania, Piazza Università, 95123 Catania, Italy (L.C.); (A.A.)
- Ophthalmology Unit, University of Siena, 53100 Siena, Italy
| | - Roberta Amato
- Eye Clinic, Catania University, San Marco Hospital, Viale Carlo Azeglio Ciampi, 95121 Catania, Italy
| | - Roberta Foti
- Eye Clinic, Catania University, San Marco Hospital, Viale Carlo Azeglio Ciampi, 95121 Catania, Italy
| | - Francesco Cappellani
- Faculty of Medicine, University of Catania, Piazza Università, 95123 Catania, Italy (L.C.); (A.A.)
- Willis Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107, USA
| | - Massimiliano Cocuzza
- Faculty of Medicine, University of Catania, Piazza Università, 95123 Catania, Italy (L.C.); (A.A.)
| | - Federico Visalli
- Faculty of Medicine, University of Catania, Piazza Università, 95123 Catania, Italy (L.C.); (A.A.)
| | - Ludovica Cannizzaro
- Faculty of Medicine, University of Catania, Piazza Università, 95123 Catania, Italy (L.C.); (A.A.)
| | - Alessandro Avitabile
- Faculty of Medicine, University of Catania, Piazza Università, 95123 Catania, Italy (L.C.); (A.A.)
| | - Giuseppe Gagliano
- Faculty of Medicine, University of Catania, Piazza Università, 95123 Catania, Italy (L.C.); (A.A.)
| | - Lucia Lapenna
- Department of Ophthalmology, Di Venere’s Hospital of Bari, Via Ospedale di Venere, 1, 70012 Bari, Italy
| | - Fabiana D’Esposito
- Imperial College Ophthalmic Research Group (ICORG) Unit, Imperial College, London NW1 5QH, UK
- GENOFTA Srl, Sant’Agnello, 80065 Naples, Italy
| |
Collapse
|